{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:42:10Z","timestamp":1787496130160,"version":"build-2736575974"},"reference-count":48,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>The cereblon modulating agents (CMs) including lenalidomide, pomalidomide and CC-220 repurpose the Cul4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase complex to induce the degradation of specific neomorphic substrates via polyubiquitination in conjunction with E2 ubiquitin-conjugating enzymes, which have until now remained elusive. Here we show that the ubiquitin-conjugating enzymes UBE2G1 and UBE2D3 cooperatively promote the K48-linked polyubiquitination of CRL4CRBN neomorphic substrates via a sequential ubiquitination mechanism. Blockade of UBE2G1 diminishes the ubiquitination and degradation of neomorphic substrates, and consequent antitumor activities elicited by all tested CMs. For example, UBE2G1 inactivation significantly attenuated the degradation of myeloma survival factors IKZF1 and IKZF3 induced by lenalidomide and pomalidomide, hence conferring drug resistance. UBE2G1-deficient myeloma cells, however, remained sensitive to a more potent IKZF1\/3 degrader CC-220. Collectively, it will be of fundamental interest to explore if loss of UBE2G1 activity is linked to clinical resistance to drugs that hijack the CRL4CRBN to eliminate disease-driving proteins.<\/jats:p>","DOI":"10.7554\/elife.40958","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T08:58:08Z","timestamp":1537433888000},"source":"Crossref","is-referenced-by-count":78,"title":["UBE2G1 governs the destruction of cereblon neomorphic substrates"],"prefix":"10.7554","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2138-1522","authenticated-orcid":true,"given":"Gang","family":"Lu","sequence":"first","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Weng","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Matyskiela","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinde","family":"Zheng","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fang","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Wood","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Surka","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Mizukoshi","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chun","family":"Lu","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Mendy","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Sock","family":"Jang","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Marella","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Couto","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Cathers","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Carmichael","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Chamberlain","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rolfe","sequence":"additional","affiliation":[{"name":"Celgene Corporation, San Diego, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1093\/emboj\/19.22.6085","article-title":"Nuclear-specific degradation of Far1 is controlled by the localization of the F-box protein Cdc4","volume":"19","author":"Blondel","year":"2000","journal-title":"The EMBO Journal"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1146\/annurev-pharmtox-010715-103507","article-title":"Targeted protein degradation by small molecules","volume":"57","author":"Bondeson","year":"2017","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nature Structural & Molecular Biology"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1074\/jbc.M114.624809","article-title":"Differential ubiquitin binding by the acidic loops of Ube2g1 and Ube2r1 enzymes distinguishes their Lys-48-ubiquitylation activities","volume":"290","author":"Choi","year":"2015","journal-title":"Journal of Biological Chemistry"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nchembio.1887","article-title":"Protein degradation: Prime time for PROTACs","volume":"11","author":"Deshaies","year":"2015","journal-title":"Nature chemical biology"},{"key":"bib6","first-page":"729","article-title":"Establishment and characterization of two human myeloma cell lines secreting kappa light chains","volume":"3","author":"Eton","year":"1989","journal-title":"Leukemia"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0092-8674(00)80404-3","article-title":"A complex of Cdc4p, Skp1p, and Cdc53p\/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p","volume":"91","author":"Feldman","year":"1997","journal-title":"Cell"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"British Journal of Haematology"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"12036","DOI":"10.1074\/jbc.274.17.12036","article-title":"Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway","volume":"274","author":"Gong","year":"1999","journal-title":"Journal of Biological Chemistry"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","article-title":"CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL","volume":"126","author":"Hagner","year":"2015","journal-title":"Blood"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","article-title":"How I treat first relapse of myeloma","volume":"130","author":"Harousseau","year":"2017","journal-title":"Blood"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annual Review of Biochemistry"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/cr.2016.31","article-title":"Drugging the undruggables: exploring the ubiquitin system for drug development","volume":"26","author":"Huang","year":"2016","journal-title":"Cell Research"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1042\/bj3540655","article-title":"Identification of Cdc6 protein domains involved in interaction with Mcm2 protein and Cdc4 protein in budding yeast cells","volume":"354","author":"Jang","year":"2001","journal-title":"Biochemical Journal"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.cell.2008.04.012","article-title":"Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex","volume":"133","author":"Jin","year":"2008","journal-title":"Cell"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.cell.2016.08.014","article-title":"Tag team ubiquitin ligases","volume":"166","author":"Kleiger","year":"2016","journal-title":"Cell"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","article-title":"The ubiquitin code","volume":"81","author":"Komander","year":"2012","journal-title":"Annual Review of Biochemistry"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1042\/EBC20170030","article-title":"Protein degradation: a validated therapeutic strategy with exciting prospects","volume":"61","author":"Lebraud","year":"2017","journal-title":"Essays In Biochemistry"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1161\/CIRCULATIONAHA.113.001551","article-title":"High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice","volume":"128","author":"Lehti","year":"2013","journal-title":"Circulation"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature05542","article-title":"A ubiquitin ligase transfers preformed polyubiquitin chains from a conjugating enzyme to a substrate","volume":"446","author":"Li","year":"2007","journal-title":"Nature"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ccr.2014.06.026","article-title":"Phosphorylation of ETS1 by src family kinases prevents its recognition by the COP1 tumor suppressor","volume":"26","author":"Lu","year":"2014","journal-title":"Cancer Cell"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of ikaros and aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.4049\/jimmunol.1601725","article-title":"Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity","volume":"199","author":"Nakayama","year":"2017","journal-title":"The Journal of Immunology"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacology & Therapeutics"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1038\/sj.onc.1207414","article-title":"Nedd8 on cullin: building an expressway to protein destruction","volume":"23","author":"Pan","year":"2004","journal-title":"Oncogene"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1093\/emboj\/20.17.4836","article-title":"Separate SCF(CDC4) recognition elements target Cdc6 for proteolysis in S phase and mitosis","volume":"20","author":"Perkins","year":"2001","journal-title":"The EMBO Journal"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrm1547","article-title":"Function and regulation of cullin-RING ubiquitin ligases","volume":"6","author":"Petroski","year":"2005","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4(CRBN) ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.biochem.70.1.503","article-title":"Mechanisms underlying ubiquitination","volume":"70","author":"Pickart","year":"2001","journal-title":"Annual Review of Biochemistry"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"10484","DOI":"10.1073\/pnas.90.22.10484","article-title":"Cloning of the human homolog of the CDC34 cell cycle gene by complementation in yeast","volume":"90","author":"Plon","year":"1993","journal-title":"PNAS"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2018.1485915","article-title":"Cereblon gene expression and correlation with clinical outcomes in patients with relapsed\/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS","author":"Qian","year":"2018","journal-title":"Leukemia & Lymphoma"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2007.05.027","article-title":"Sequential E2s drive polyubiquitin chain assembly on APC targets","volume":"130","author":"Rodrigo-Brenni","year":"2007","journal-title":"Cell"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"PNAS"},{"key":"bib40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212916","article-title":"Cereblon modulator iberdomide induces degradation of the transcription factors ikaros and aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus","volume":"77","author":"Schafer","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.cell.2016.07.027","article-title":"Two distinct types of E3 ligases work in unison to regulate substrate ubiquitylation","volume":"166","author":"Scott","year":"2016","journal-title":"Cell"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1128\/MCB.05496-11","article-title":"Selective ubiquitylation of p21 and Cdt1 by UBCH8 and UBE2G ubiquitin-conjugating enzymes via the CRL4Cdt2 ubiquitin ligase complex","volume":"31","author":"Shibata","year":"2011","journal-title":"Molecular and Cellular Biology"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0092-8674(00)80403-1","article-title":"F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex","volume":"91","author":"Skowyra","year":"1997","journal-title":"Cell"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"DRUG DEVELOPMENT. phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.molcel.2010.02.025","article-title":"Priming and extending: a UbcH5\/Cdc34 E2 handoff mechanism for polyubiquitination on a SCF substrate","volume":"37","author":"Wu","year":"2010","journal-title":"Molecular Cell"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective small molecule induced degradation of the BET bromodomain protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chemical Biology"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/40958\/elife-40958-v2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/40958\/elife-40958-v2.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/40958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:01:55Z","timestamp":1697058115000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/40958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":48,"alternative-id":["10.7554\/eLife.40958"],"URL":"https:\/\/doi.org\/10.7554\/elife.40958","archive":["CLOCKSS"],"relation":{"has-review":[{"id-type":"doi","id":"10.7554\/eLife.40958.032","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.40958.033","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1101\/389098","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"article-number":"e40958"}}